CompanyGraph
Neurocrine Biosciences Inc.
NBIX · United States
Makes and sells INGREZZA, a drug that treats uncontrolled movement disorders by reducing dopamine release in the brain.
Neurocrine Biosciences sells INGREZZA, a drug that treats movement disorders like tardive dyskinesia by reducing how much dopamine the brain releases, rather than blocking where dopamine lands — a mechanistic difference it proved through years of controlled head-to-head trials against older treatments. Because those trials generated a clinical dataset tied specifically to valbenazine, no competitor can borrow or license that proof; a rival would have to run equivalent trials on their own distinct molecule, which takes years and produces data about that molecule alone. Neurologists who have internalized the dosing protocol for INGREZZA are slow to switch, and pharmacy benefit managers follow their prescribing habits when setting formulary coverage, so the reimbursement position flows downstream from the clinical evidence. The whole structure rests on one underlying bet: that VMAT2 inhibition stays the accepted target for these conditions — if a safety concern emerged or a rival mechanism proved superior, the prescriber habits, formulary slots, and next-generation pipeline drug NBI-1065890 would all lose their foundation at once.
How does this company make money?
The company earns revenue each time a prescription for INGREZZA is filled through a specialty pharmacy. The total amount it collects depends on how many movement disorder specialists are writing those prescriptions and on the reimbursement rates the company has negotiated with pharmacy benefit managers and Medicare Part D plans, which set how much of the drug's price is actually paid.
What makes this company hard to replace?
Neurologists who prescribe INGREZZA have learned a dosing protocol built around its specific receptor profile, which works differently from dopamine receptor antagonists used in older treatments. Switching to an alternative means learning a new protocol from scratch. For patients, stopping INGREZZA and starting a different drug means going through a titration period — a gradual dose adjustment phase — during which their movement disorder symptoms can return or worsen before the new drug takes effect.
What limits this company?
Making valbenazine, the active ingredient in INGREZZA, requires specialized chemical equipment and tightly regulated manufacturing facilities in San Diego. How much drug can be produced depends on how much those validated facilities can handle, not on how many patients want it. And because each new drug in the pipeline — like NBI-1065890 — needs its own completely separate manufacturing process and FDA approval, the company cannot reuse or expand the INGREZZA factory to speed up new products.
What does this company depend on?
The company cannot operate without FDA approval covering INGREZZA's tardive dyskinesia and Huntington's chorea indications, suppliers who provide the chemical building blocks for valbenazine synthesis, Good Manufacturing Practice-compliant production facilities in San Diego, movement disorder specialist prescriber networks who write the prescriptions, and pharmacy benefit managers whose formulary decisions determine whether patients can afford the drug.
Who depends on this company?
Movement disorder neurologists treating tardive dyskinesia patients would lose the only VMAT2 inhibition option those patients currently have. Specialty pharmacies that distribute INGREZZA would lose a significant source of movement disorder revenue. Huntington's disease treatment centers that rely on VMAT2 inhibition to manage chorea symptoms would have no equivalent replacement. Patients with tardive dyskinesia would be pushed back to older dopamine-blocking drugs that are less selective and carry different risks.
How does this company scale?
Getting INGREZZA to more patients is relatively cheap because the company can use existing specialty pharmacy networks and movement disorder treatment centers without building new infrastructure. What does not scale easily is developing new drugs: each next-generation molecule like NBI-1065890 needs its own synthesis process, its own bioequivalence studies, and its own separate FDA approval, none of which can be shared with INGREZZA or automated across the pipeline.
What external forces can significantly affect this company?
Changes to Medicare Part D formularies can directly raise or lower what elderly tardive dyskinesia patients pay out of pocket, which affects how many fill their prescriptions. Decisions by the European Medicines Agency on whether to approve VMAT2 inhibitors will determine whether the company can sell into international markets. And as the population ages and more people take long-term antipsychotic drugs, the number of patients who develop tardive dyskinesia is likely to grow, which increases the potential pool of INGREZZA users.
Where is this company structurally vulnerable?
If new clinical evidence showed that blocking VMAT2 causes a serious safety problem, or that a completely different biological pathway works better for tardive dyskinesia or Huntington's chorea, the trial data that makes neurologists choose INGREZZA would become worthless overnight. That would remove INGREZZA from formularies, collapse prescriber confidence, and kill the pipeline value of NBI-1065890 at the same time, because every asset the company owns is built on the assumption that VMAT2 inhibition is the right target.